The biomedicine industry in the Guangzhou Development District has received a major boost following the arrival of new world-leading bio-pharmaceutical companies.

On Dec 10, American Fortune 500 multinational conglomerate GE, which occupies a strong position within the healthcare sector, along with Swiss pharmaceutical giant Lonza, signed cooperation agreements with the Guangzhou Development District. 

Lonza will set up an independent legal entity in Sino-Singapore Guangzhou Knowledge City (SSGKC), invest in biomedical production projects and produce biopharmaceuticals from the pre-clinical to early commercial stages. It will also engage in technological innovation and help biopharmaceutical companies develop new therapies to help commercialize their products. Lonza also revealed plans to launch new production projects in the Biomedicine Value Innovation Park in SSGKC.

In June 2017, construction on GE's first biotechnology park in Asia began in SSGKC. GE got involved in Guangzhou by making use of the city's talent-training and support services. In order to provide personalized training to talents in the biopharmaceutical industry, it introduced the advanced biotechnology research and training institute and jointly developed the first international biotechnology training center in Guangzhou with the help of the Guangzhou Development District. It also invested in the construction of the GE Water Chemical Plant to provide biopharmaceutical companies inside and outside the park with aqueous solution for the production of biomedicine.